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Objective: The present study was aimed to develop of the Guanfacine Hydrochloride Extended-release tablets for the treatment of Attention Deficit 
Hyperactivity Disorder (ADHD). The dosage regimen of Guanfacine Hydrochloride is 4 mg at every 6 h. The concentration of Guanfacine in plasma is 
fluctuating. Hence, to control the plasma fluctuation and to avoid toxicity problem, Guanfacine Hydrochloride was chosen as a drug with an aim to 
develop an extended release system for 20 to 24 h.  
Methods: The design of the system was based on the use of pH-dependent polymer (Hydroxypropyl Methyl Cellulose), pH-independent polymer 
(Eudragit L 100-55), along with microenvironment modifiers such as organic acid (Fumaric acid) were used in the formulation. Drug-excipient 
compatibility was studied by FTIR. Before compression, the granules were evaluated for precompression parameters such as bulk density, tapped 
density, an angle of repose, compressibility index and Hausner’s ratio. After compression, evaluation tests of tablets such as general appearance, 
hardness, thickness, weight variation, friability, content uniformity, in vitro release studies and stability studies were performed.  
Results: Out of 9 formulations, the drug release was found to be within the innovator formulation F9. The stability study of formulation F9 revealed 
there was no significant change in physical and chemical properties of drug stored at 40 °C/75 % RH, 30 °C/65 % RH, 25 °C/60 % RH for 2 mo.  
Conclusion: Optimized formulation batch F9 showed highest F2 value which indicates similarity with innovator product. The study indicates that 
Guanfacine Hydrochloride Extended-release tablet was successfully developed.  
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Oral drug delivery has been known for decades as the most widely 
utilized route of administration for delivery of drugs via different 
dosage forms due to its ease of administration, high patient 
compliance and flexibility in the design of dosage form. The goal of 
any drug delivery system is to provide a therapeutic amount of drug 
to proper site in the body to achieve promptly and then maintain, 
the desired drug concentration. The design of a proper dosage 
regimen is an important element in accomplishing this goal [1, 2].  
Conventional oral drug delivery systems are slowly fading away 
in the market owing to disadvantages. These delivery systems 
produce fluctuation of drug plasma level that either exists at a 
safe therapeutic level or quickly falls below the minimum 
effective level. This effect is usually totally dependent on the 
particular agent’s biological half-life, the frequency of 
administration and release rate. It is recognized that many 
patients can benefit from drugs intended for chronic 
administration by maintaining the plasma level within a safe 
effective range [3]. Extended oral drug delivery systems are 
highly recognized today for their benefits, improving the 
disadvantages of conventional drug delivery systems. 
To be a successful, extended-release [ER] products the drug must be 
released from the dosage from at a predetermined rate in 
gastrointestinal fluids, maintain sufficient gastrointestinal residence 
time and be absorbed at a rate that will replace the amount of drug 
being metabolized and excreted. Extended drug delivery systems are 
used in the treatment of chronic rather than the acute condition, and 
they process a good margin of safety [4-6]. 
While psychostimulant medications have large effect sizes for 
treatment of attention-deficit/hyperactivity disorder (ADHD) 
symptoms. Guanfacine is a selective alpha2-agonist that shares some 
pharmacological properties with the non-selective alpha2-agonist 
clonidine [7].  
The aim of this research work was to formulate guanfacine 
hydrochloride (HCl) ER tablet which delivered drug for 24 h.  
MATERIALS AND METHODS 
Materials 
Guanfacine HCl was supplied by Intas Pharmaceutical. H. P. M. C, 
Methacrylic Acid (Eudragit L100-55), Microcrystalline Cellulose PH-
102, Lactose Monohydrate, Fumaric Acid, Glyceryl Behenate, Lake Of 
Indigo Carmine, Ferric Oxide Yellow from Evonik Signet Chemical 
Corporation Pvt. Ltd. Industries, Mumbai. All other chemicals used 
were of analytical grade. 
Methods 
Preformulation study  
Organoleptic properties 
The drug samples were evaluated for its colour, odour, taste and 
appearance. The result was mentioned in table 3. 
Melting point 
The melting point was determined by the melting point apparatus. 
The temperature at which drug melted was recorded the result was 
mentioned in table 3. 
Solubility 
For the determination of solubility, an excess amount of drug was 
added in the solvent (water, 0.1N HCl, Acetate buffer pH 4.5, 
Phosphate Buffer pH 6.8) at room temperature and kept for 48 h 
with occasional shaking. The supernatant was taken and analyzed by 
using Shimadzu UV 1800 double beam spectrophotometer. The 
results were mentioned in table 4. 
Differential scanning calorimetry (DSC) 
The DSC study was carried out for the obtained sample of guanfacine 
HCl to confirm its purity. The DSC patterns were recorded on a 
METTLER TOLEDO STARe System. 1.5 mg of drug was heated in 
crimped aluminium pans at a scanning rate of 400 °C/min in an 
atmosphere of nitrogen gas flow 40 ml/min using the range of 40-
350 °C. The DSC curve was shown in fig. 1. 
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Formulation development 
The primary aim of this development work was to produce a stable 
and bioequivalent formulation as compare to that of reference 
formulation. The formulation development work was undertaken 
considering the following approaches [8-11]. 
Direct compression 
The range of concentration of release modifier was also based on 
the patent of the innovator’s product. i.e. Concentration of 
hydroxypropyl methylcellulose (HPMC) as shown in the 
following table. 
 
Table 1: Batch formula 
S. No. Ingredients Batch codes (Quantity in mg/tab) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1. Guanfacine HCl 4.59 4.59 4.59 4.59 4.59 4.59 4.59 4.59 4.59 
2. Microcrystalline cellulose  50 82 38.21 38.21 47.21 47.21 41.21 75.21 41.2 
3. Methacrylic acid  60 40 60 60 65 70 70 70 70 
4. HPMC  49 55 60 60 35 30 30 30 30 
5. Lactose monohydrate  52.20 52.20 57 57 49 49 - - - 
6. Lake of Indigo Carmine 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 
7. Ferric oxide yellow 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 
8. Fumaric acid 10 12 13 13 18 18 - 18 18 
9. Glyceryl behenate 36 20 26 26 40 40 40 26 40 
10. Ludipress - - - - - - 60 50 40 
  
Compatibility study of drugs with Excipients 
FTIR 
FTIR spectra of pure drug and conventional and ready base 
approach formulations of these excipients with the drug were 
recorded on Agilent FTIR spectrophotometer. The instrument was 
operated under dry air purge and the scans were collected with a 
resolution of 4 cm-1 over the region 4000-650 cm-1. 
Evaluation of granules 
Bulk density 
Bulk Density is the ratio of the weight of powder to the volume it 
occupies. It is expressed as g/ml. 
Flow property 
Compressibility is indirectly related to the relative flow rate, 
cohesiveness and particle size distribution of the powder. Tapped 
and untapped bulk density measurements can estimate the 
compressibility of a material 
Selection of dissolution media 
Dissolution media was selected based on the dissolution database 
published in literature available and based on the solubility and 
stability of the dosage form and considering the intended use of 
the dosage form. The HCl Buffer pH 2.2, Acetate Buffer pH 4.5, 
Phosphate Buffer pH 6.8 media were selected for dissolution 
profile. 
Characterization of an innovator product 
Physical characterization 
The reference product for guanfacine HCl is INTUNIV Tablets 
manufactured by Shire Inc. The developmental work was done 
considering innovator product i.e. INTUNIV 4 mg Tablets. The 
physical characteristics of the INTUNIV 4 mg Tablets are given in. 
 
Table 2: Product details of intuniv 4 mg 
S. No. Description Intuniv 4 mg tablet 
1 Name of Product Intuniv Tablets 4 mg  
2 Label Claim Contains Guanfacine HCl eq. to 4 mg of Guanfacine 
4 Manufactured By Shire US Inc, Wayne, PA 19087, Made in USA 
5 Market  US 
6 Dosage form details  
6.1 Dosage form ER Tablet 
6.2 Shape Capsule-shaped, Biconvax 
6.3 Color  Green 
6.4 Size (Length X Width) 12.31 X 6.10 mm 
6.5 Thickness 4.15 mm 
6.6 Average weight 268 mg 
 
Comparison of dissolution profiles for selection of optimized batch 
The similarity factor (f2) given by SUPAC guidelines for a modified 
release dosage form was used as a basis to compare dissolution 
profiles. The dissolution profiles are considered to be similar when 
f2 is between 50 and 100. The dissolution profile of products were 
compared using a f2 which is calculated from the following formula, 
 
Where n is the dissolution time and Rt and Tt are the reference (here 
is the theoretical dissolution profile of guanfacine HCl) and test 
dissolution value at time t48. All Factorial design batches (F1 to F8) 
were compared with the theoretical profile for calculation of 
similarity factor. 
Stability study  
The stability study is performed to check the physical-chemical 
integrity of the product. For performing the stability study storage 
condition was determined based on ICH Guidelines. The selected F9 
batch was subjected to stability study [12-15]. 
RESULTS AND DISCUSSION  
Preformulation study 
The received samples were identified by various tests. The results 
are as shown below. 
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Table 3: Organoleptic properties of guanfacine HCl 
S. No. Organoleptic properties Observations Specification 
1.  Colour White or off white White or off white 
2.  Odour Odourless Odourless 
3.  Description Crystalline powder Crystalline powder 
4.  Melting Point 226 °C 225 °C-227 °C 
 
Table 4: Solubility profile of guanfacine HCl 
S. No. pH solubility profile Solubility (mg/ml) 
1 Water 0.163 
2 0.1 N HCl 0.420 
3 Acetate buffer pH 4.5 1.265 
4 Phosphate buffer pH 6.8 1.302 
  
Based on Organoleptic properties and solubility studied drug was 
characterized for the above parameters which were found to be 
similar and complies with the standard specification. Hence the 
guanfacine HCl was identified and considered to be pure. 
 
 
Fig. 1: DSC thermogram of guanfacine HCl 
 
Differential scanning calorimetry (DSC) 
The DSC spectrum of guanfacine HCl was obtained and is given in fig. 
1. Drug shows Sharp melting endotherm at 225 °C, which is the 
melting point of the drug. 
Thermal analysis showed a characteristic sharp endothermic peck at 
225.67 °C indicating the melting point of the drug. The fact 
confirmed the obtained drug was pure and in crystalline form. 
Analytical methods 
UV spectroscopy 
Calibration curves of guanfacine HCl were carried out in different 
media like methanol, 0.1 N HCl and Phosphate buffer pH 6.8 
Calibration curve in Methanol, 0.1N HCl and Phosphate buffer pH 6.8 
were found to be linear having R2 value 0.9992, 0.9907, 0.9992 
respectively as shown in fig. 2. 
FTIR compatibility study 
To check the interaction between drug and excipients used in the 
formulations, FTIR studies were performed. 
These peaks were not affected and prominently observed in FTIR 
spectra given in fig. 3 Thus, we can say that there was no significant 
interaction between drug and excipients were observed. 
 
 
Fig. 2: Calibration curve in Methanol, 0.1N HCl, Phosphate buffer pH 6.8 
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Fig. 3: FTIR spectrum of drug and physical mixture 
 
Table 5: Physical evaluation of granulation batches 
Batch code F1 F2 F3 F4 F5 F6 F7 F8 F9 
Bulk density (g/ml) 0.428 0.457 0.604 0.667  0.646 0.626 0.410 0.528 0.475 
Tap density (g/ml) 0.545 0.592 0.760 0.771 0.729 0.724 0.508 0.624 0.552 
Carr’s Index (%) 21.46 22.80 20.54 13.48  13.02 13.52 19.29 15.31 13.92  
Hausner’s Ratio 1.27 1.29 1.25 1.15 1.12 1.15 1.23 1.18 1.16 
 
Evaluation of granules  
Physical Evaluation of granulation batches was indicated in table 5. 
The Carr’s Index and Hausner’s Ratio was indicated blend showed 
good physical property and did not show any issue regarding weight 
variation and indicates that direct compression method was 
suitable. 
Formulation development  
Physical characteristics  
Physical characteristics data such as average weight, hardness, 
thickness, assay, friability were mentioned in table 6. Results 
revealed that assay has a more significant effect on the dissolution 
profile of guanfacine HCl ER formulation. 
 
Table 6: Physical evaluation of tablet 
Physical parameter  
Batches  Average Weight (mg)  Hardness (N)  Thickness (mm)  Friability (%)  Assay (%)  
F1  265  10±6.05  4.30-4.40  0.89±0.011  85.50  
F2  265  50±7.8  4.60-4.70  0.65±0.012  92  
F3  260 90±2.25  4.35-4.45  0.213±0.018  79.82  
F4  260 110±2.06  4.45-4.55  Nil  89  
F5  260 100±2.54  4.45-4.55  0.132±0.018  99  
F6  265 110±3.05  4.20-4.30  0.215±0.021  98.5  
F7  267.20  100±6.52  4.40-4.50  0.220±0.017  99.66  
F8  265 110±7.52  4.45-4.465  0.154±0.022  99.2  
F9  265 110±6.22  4.36-4.42  0.142±0.025  98.4  
 
Dissolution study 
Dissolution Profile of Intuniv tablet 4 mg. (innovator) was carried 
out in a different solvent. Comparative study were carries out 
between formulated batches F1-F9 and Intuniv tablet. From the 
above result, it was observed that Intuniv 4 mg tablet showed 
more release in a phosphate buffer solution having pH 6.8 The 
above-mentioned results of F1-F9 batch % cumulative drug 
released in 6.8 pH phosphate buffer with USP apparatus type II 
indicates F1-F3 batch showed less released after 24 h compared to 
remaining batches. Batch F9 showed good similarity with the 
innovator product. 
Statistical treatment of dissolution data 
The values of similarity factor (f2) for the batch F9 showed 
maximum f2 value 85.42 as shown in table 7.  
Hence, formulation batch F9 was considered as an optimum batch. 
Desai et al. 
Int J App Pharm, Vol 11, Issue 3, 2019, 43-48 
47 
 
Fig. 4: Dissolution profile of intuniv 4 mg tablet 
 
Fig. 5: Dissolution profile of intuniv 4 mg tablets and F1-F9 batch 
 
Table 7: Similarity factor (f2) for F1-F9 
Batch F1 F2 F3 F4 F5 F6 F7 F8 F9 
Similarity Factor 40.5 46.75 33.1 51.02 59.37 67.97 74.24 71.87 85.42 
 
Table 8: Stability evaluation of optimized batches 
Batch No. F9 
Test Condition 40 °C/75 % RH 30 °C/65 % RH 25 °C/60 % RH 
Initial 1 Mo 2 Mo 1 Mo 2 Mo 1 Mo 2 Mo 
Description  Light Green Oval Shaped 
Assay 99.5 % 98.9 % 99 % 98.2 % 99.4% 99.3% 99.2% 
Hardness 90 N 82 N 85 N 80 N 86 N 90 N 87 N 
Avg. Wt. (mg) 265 264. 8 264.8 265 265 265 265 
Time (Hrs) % DR in Phosphate 6.8 
1 9.21 8.56 7.98 8.41 7.64 8.47 8.1 
4 34.42 37.52 38.24 36.45 39.14 38.42 37.2 
8 64.22 66.41 62.45 63.25 65.12 61.45 69.75 
12 84.65 86.14 82.14 84.12 81.85 85.45 86.58 
18 91.56 92.45 94.12 90.12 91.46 92.84 92.56 
24 96.14 97.12 97.52 95.6 96.42 97.46 96.12 
 
Stability study 
Stability study of optimized batch F9 was carried out and results as 
shown in table 8. 
The above table shows that there was no considerable changes in 
appearance, physical parameter and chemical parameters of the 
formulation after stability study. From observed results, it was 
stated that the prepared tablet was found to be stable.  
CONCLUSION 
The focus of the current study was to develop the extended-release 
tablet of guanfacine HCl using a direct compression method. In this 
developed formulation pH-dependent and pH-independent 
polymers such as Hydroxy Propyl methylcellulose and Eudragit 
L100–55 were utilized to prepare matrix tablets. 
Incompatibility study IR, it was observed that the drug was in pure 
form and there were no major interactions with other polymers. The 
in vitro dissolution study revealed that the batch F9 was best among 
nine batches been prepared and showed a similar release pattern 
with innovator product. Stability study of the optimized batch was 
carried out at 40 °C/75 % RH, 30 °C/65 % RH, 25 °C/60 % RH. It 
was found that there was no statistically significant difference in in 
vitro drug release before and after stability study. Thus, from the 
above conclusion, it is summarized that the formulation and 
evaluation of guanfacine HCl extended-release tablet was 
successfully prepared by using a direct compression method. 
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